- Home
- SVRA vs GAM Comparison
SVRA vs GAM Comparison
Compare SVRA & GAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SVRA | GAM |
|---|---|---|
| Founded | 2007 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | SVRA | GAM |
|---|---|---|
| Price | $5.30 | $60.39 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $7.33 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 20.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 5.74% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 11.67 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.14 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $41.80 |
| 52 Week High | $7.01 | $64.40 |
Technical Indicators
Market Signals| Indicator | SVRA | GAM |
|---|---|---|
| Relative Strength Index (RSI) | 40.47 | 39.19 |
| Support Level | $5.10 | $56.26 |
| Resistance Level | $6.06 | $61.14 |
| Average True Range (ATR) | 0.31 | 0.85 |
| MACD | -0.03 | -0.19 |
| Stochastic Oscillator | 6.42 | 0.36 |
Price Performance
Historical ComparisonAbout SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.